GlassScriptPhysician profile
Katelyn Meissner
NPI 1598317760
$1,690.11
in general payments reported to CMS, 2019-2025
33 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $508 · 2023: $149 · 2024: $503 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.36 |
| Education | $138.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $176.29 | 2021-2024 | |
| Janssen Biotech, INC. | $158.81 | 2024 | Carvykti, Darzalex, Tecvayli |
| Beone Medicines USA, INC. | $131.19 | 2025 | Brukinsa |
| Beigene USA, INC. | $127.37 | 2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $105.41 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $95.86 | 2022-2024 | |
| Glaxosmithkline, LLC. | $91.49 | 2024 | Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $88.14 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $64.31 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $55.61 | 2021-2022 | |
| Lilly USA, LLC | $49.50 | 2022-2025 | Jaypirca |
| Karyopharm Therapeutics INC. | $47.37 | 2022-2023 | Xpovio |
| Servier Pharmaceuticals LLC | $46.97 | 2021-2022 | |
| Eisai INC. | $39.58 | 2022 | |
| Amgen INC. | $38.86 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $33.92 | 2021 | |
| Merck Sharp & Dohme LLC | $31.55 | 2024 | Keytruda |
| Dendreon Pharmaceuticals LLC | $29.78 | 2021-2022 | |
| Coherus Oncology, INC. | $28.92 | 2021 | |
| Adc Therapeutics America, INC. | $27.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.48 | 2025 | Opdivo |
| Genzyme Corporation | $22.02 | 2021 | |
| Agios Pharmaceuticals, INC. | $19.87 | 2022 | |
| Pfizer INC. | $19.36 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.61 | 2021 | |
| Seagen INC. | $16.99 | 2021 | |
| Puma Biotechnology, INC. | $16.31 | 2022 | |
| Taiho Oncology, INC. | $15.95 | 2022 | |
| Daiichi Sankyo INC. | $15.61 | 2022 | |
| Exelixis INC. | $15.03 | 2025 | Cabometyx |
| Morphosys, US INC. | $12.19 | 2021 | |
| Abbvie INC. | $12.13 | 2021 | |
| Organon LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Meissner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.